LY2940680 is a potent and selective antagonist of the Hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor. This compound has been investigated primarily for its potential in cancer therapy, particularly in tumors driven by aberrant activation of the Hedgehog pathway. It shows promise in the treatment of advanced or metastatic basal cell carcinoma and other solid tumors where Hedgehog signaling plays a key role in tumor growth and progression. Due to its ability to overcome resistance to other SMO inhibitors, LY2940680 has been studied in patients who have relapsed after prior Hedgehog pathway inhibitor therapy. Its development focuses on improving clinical outcomes in oncology by blocking downstream signaling events that promote cell proliferation and survival in certain cancers.